Isolated ACTH deficiency during single-agent pembrolizumab for squamous cell lung carcinoma: a case report

BACKGROUND: The programmed cell death 1 (PD-1) inhibitor pembrolizumab is a promising agent for treatment of several different malignancies, but as with all immunotherapy there is a potential risk of immune-related adverse events. Adrenocorticotropic hormone (ACTH) deficiency and hypophysitis have b...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Sho, Kushimoto, Masaru, Nishizawa, Tsukasa, Takubo, Masahiro, Mitsuke, Kazutaka, Ikeda, Jin, Fujishiro, Midori, Ogawa, Katsuhiko, Tsujino, Ichiro, Suzuki, Yutaka, Abe, Masanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945618/
https://www.ncbi.nlm.nih.gov/pubmed/31921440
http://dx.doi.org/10.1186/s40842-019-0092-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945618/
https://www.ncbi.nlm.nih.gov/pubmed/31921440
http://dx.doi.org/10.1186/s40842-019-0092-9

Ejemplares similares